The damaging impact of tariffs on intellectual property

April 30, 2025

This article was originally published in IAM on April 24th, 2025

By Kirti Gupta

Economic statecraft has reached new levels with the United States levying the steepest increase in tariffs on foreign goods in the last 150 years. While the focus of these tariffs in popular media is consumer goods, we all live in the knowledge economy.

A few decades ago, 80% of the market value of S&P 500 firms was explained by their labour and capital assets. Today, that has reversed: 80% of their market value is explained by intangible assets – ideas, know-how, and intellectual property (IP).

What is the impact of the impact of these tariffs on IP? Some economists have been analyzing this question lately. The brief answer is that IP licensing revenues of US companies are likely to decrease, and IP enforcement abroad is likely to weaken, unless specific action is taken to counteract these effects proactively.

Read the full article in IAM.

Andrei Iancu – Congressional Testimony: Hearing on the Patent Eligibility Restoration Act (PERA)

October 13, 2025
On October 8th, 2025, Andrei Iancu testified before the Senate Judiciary Committee, Subcommittee on Intellectual Property during the Hearing on the Patent Eligibility Restoration Act (PERA). Iancu, Partner at Sullivan & Cromwell, former Under Secretary of Commerce for IP and Director of the U.S. Patent and Trademark Office (USPTO), and
Read More

How Europe Lost Global Biopharmaceutical R&D Leadership to the United States: Lessons for Today

September 9, 2025
By Anne Prichett Today, the United States leads the world in biopharmaceutical industry research and development (R&D), supporting nearly five million jobs and generating more than $1.65 trillion in economic output. This position of global leadership, however, is relatively recent. Until the late 1980s, Europe–particularly Germany, France,
Read More

If Private Sector R&D Is the Future, IP Policy Must Catch Up

September 8, 2025
By Chris Borges The President’s Budget Request for fiscal year 2026 (FY 2026) includes steep cuts to federal research and development (R&D) funding—a troubling signal for U.S. innovation and economic security. While congressional committees may push back on the most severe reductions, the signs are clear: Federal R&D funding is likely
Read More